Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia

Translational PsychiatryScott Cunningham MD PhD, et al. | November 23, 2022



Although 25%-33% patients with schizophrenia are not affected by cognitive impairment, for those patients who are affected, the prospects for independent living and employment are negatively impacted. No treatments for cognitive impairment in patients with schizophrenia are currently approved.

The current study showed that treatment of patients with schizophrenia and cognitive impairment using the investigational drug, KarXT (xanomeline-trospium) was safe, effective, and well-tolerated.

Data were obtained from the randomized, double-blind, placebo-controlled EMERGENT-1 trial. One hundred twenty-five patients with schizophrenia underwent cognitive assessment using the Cogstate Brief Battery before and after 5-week treatment with KarXT.

Treatment of patients with schizophrenia and cognitive impairment at baseline had significant improvement after treatment with KarXt compared to placebo.